Summary
- Greenoaks and Sequoia Capital co-led Isomorphic Labs' $5bn Series C round, with further investment from Alphabet.
- The funding will support its IsoDDE drug design engine, therapeutic pipeline and clinical development infrastructure.
- Internal oncology and immunology programmes have produced company-reported positive preclinical findings, but clinical efficacy remains untested.
London-based Isomorphic Labs has secured $5 billion to expand its artificial intelligence drug design technology and advance potential medicines towards clinical trials, adding substantial capital to a business seeking to turn computational research into therapeutic development.
The Series C round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and other new investors. Alphabet, which already backs the company, has also made a significant further investment.
Announced on 17 November, the financing follows a $2.1 billion Series B round completed in May 2026. Isomorphic intends to use the additional resources to develop its proprietary drug design platform, expand internal and partnered research programmes, and establish infrastructure supporting clinical development.
The company reports positive preclinical results from research in oncology and immunology, but has not published detailed datasets establishing the performance of individual therapeutic candidates. Its medicines have yet to demonstrate safety or efficacy through human clinical trials.
Drug discovery involves more than molecular structure
Isomorphic Labs was established in 2021 following advances in protein structure prediction associated with Google DeepMind’s AlphaFold research.
Predicting how proteins are structured can help scientists understand biological processes and investigate interactions that may be relevant to developing medicines. However, identifying a potential drug requires more than understanding the shape of a biological target.
Researchers must establish whether a compound interacts with the intended molecule in a useful way, whether it remains sufficiently stable and whether its behaviour is likely to create unwanted effects elsewhere in the body.
These requirements involve experimental biology, chemistry and pharmacology alongside computational modelling.
Isomorphic has developed its Drug Design Engine, known as IsoDDE, to help researchers assess molecular interactions and identify candidates for further investigation.
The platform combines advanced AI models with tools intended to guide the design and optimisation of compounds. The company is also developing specialised agents that can investigate complex biological questions and support parts of the research process.
By examining large numbers of possible molecular structures computationally, developers may be able to concentrate laboratory resources on candidates considered more promising.
However, a high predicted probability of interaction with a biological target does not establish that a compound will become an effective medicine.
Some compounds may fail because they cannot reach the intended tissue or because their behaviour creates unacceptable toxicity. Others may interact successfully with a target without producing a meaningful therapeutic benefit.
AI may improve decisions about which experiments to conduct, but biological testing remains necessary to determine whether the resulting predictions are reliable.
Preclinical findings support further development
Isomorphic reports encouraging results from its internal oncology and immunology programmes, alongside progress in research conducted with pharmaceutical partners.
Oncology applications involve diseases with complex biological mechanisms and substantial variation between patients, while immunology programmes must account for interactions within the body’s immune system.
Both fields can provide demanding tests of computational drug design because the effects of a candidate compound may depend on biological processes extending beyond its immediate target.
The company describes its preclinical findings as positive, but has not disclosed sufficient detail to assess the strength of the evidence independently.
Information about individual candidate molecules, experimental methods, measured effects and safety findings would be necessary to establish what those results demonstrate.
Even successful preclinical research does not guarantee progress through subsequent development. Candidates may encounter problems during further laboratory work, manufacturing or human testing.
Isomorphic’s existing collaborations include pharmaceutical groups Novartis and Johnson & Johnson, which bring additional therapeutic research and development capabilities.
Such arrangements can allow specialist AI developers to contribute computational technology while established pharmaceutical businesses provide expertise in experimental programmes and later development stages.
Commercial agreements may generate research payments, milestone income or future royalties, but those outcomes depend on the contracts and the success of individual programmes.
The presence of recognised pharmaceutical partners therefore provides evidence of commercial interest in the platform, rather than confirmation that any medicine will ultimately be approved.
Clinical development introduces new requirements
The latest investment is intended partly to prepare Isomorphic for the transition from drug discovery towards clinical studies.
That process requires capabilities extending beyond model training and molecular analysis. Companies must prepare suitable preclinical evidence, establish manufacturing arrangements and develop the quality and regulatory systems needed to investigate potential medicines in humans.
Clinical trials require defined protocols, patient recruitment, safety monitoring and methods capable of determining whether a treatment produces meaningful benefits.
Regulatory authorities also need evidence that investigational products have been manufactured and assessed according to applicable standards.
Isomorphic intends to build AI-led bioengineering and clinical development infrastructure to support these activities.
Computational methods could help researchers identify promising development strategies, interpret experimental information or design more informative studies. However, the use of AI does not remove the scientific and regulatory requirements governing the assessment of medicines.
Human testing is particularly important because experimental models cannot reproduce every aspect of a patient’s response to treatment.
Compounds showing promising effects during laboratory research may prove ineffective in clinical trials or produce adverse effects that prevent further development.
Isomorphic has not announced a definitive timetable for the first human trials associated with its new programmes. The financing supports its ability to pursue clinical development but does not establish that individual candidates have passed the necessary milestones.
Record financing carries long development horizons
The $5 billion Series C represents substantial investor confidence in AI-assisted drug discovery and the commercial potential of Isomorphic’s research platform.
Combined with May’s $2.1 billion Series B, the company has raised $7.1 billion across those two financing rounds alone.
That capital gives Isomorphic resources to recruit specialist researchers, expand computing and laboratory capabilities, and support programmes that may require years of development before reaching patients.
Unlike enterprise software businesses, drug developers cannot necessarily convert promising research into revenue soon after completing a technical demonstration.
Laboratory testing, manufacturing development and clinical studies are expensive, while the risk of failure remains substantial throughout the process.
Isomorphic’s commercial approach combines proprietary therapeutic programmes with research partnerships, potentially creating different sources of value as its technology develops.
The internal pipeline could eventually produce licensing opportunities or medicines for further commercial development, while partnerships may generate payments tied to research and development milestones.
Neither route guarantees financial returns. The value of AI-assisted discovery will be demonstrated through improved decisions, reproducible experimental results and ultimately the outcomes of individual medicines.
The company’s London operations also connect the investment to the UK’s AI and life sciences sectors, where advanced computing, laboratory expertise and clinical research capabilities are increasingly being brought together.
However, the size of the financing should not be confused with a valuation or proof of clinical success. Isomorphic has not disclosed a company valuation for the Series C, and its reported preclinical progress remains subject to further scientific validation.
The additional capital strengthens its ability to pursue therapeutic development. The more consequential milestones will involve disclosure of experimental evidence, progression of specific drug candidates and the results of clinical studies when those programmes reach human testing.












